|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
JP4524072B2
(ja)
|
2000-10-23 |
2010-08-11 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
新規化合物
|
|
DE60303009T2
(de)
|
2002-01-22 |
2006-07-13 |
Warner-Lambert Co. Llc |
2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
|
|
MXPA04010267A
(es)
|
2002-04-19 |
2005-02-03 |
Smithkline Beecham Corp |
Compuestos novedosos.
|
|
JP2005531574A
(ja)
|
2002-05-22 |
2005-10-20 |
アムジエン・インコーポレーテツド |
痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
|
|
AR041191A1
(es)
|
2002-08-08 |
2005-05-04 |
Amgen Inc |
Ligandos del receptor vanilloide y su uso en tratamientos
|
|
JP4053073B2
(ja)
*
|
2003-07-11 |
2008-02-27 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
選択的cdk4阻害剤のイセチオン酸塩
|
|
SG145695A1
(en)
*
|
2003-07-29 |
2008-09-29 |
Xenon Pharmaceuticals Inc |
Pyridyl derivatives and their use as therapeutic agents
|
|
NZ545265A
(en)
|
2003-07-30 |
2009-11-27 |
Xenon Pharmaceuticals Inc |
Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
|
|
JP4741491B2
(ja)
*
|
2003-08-07 |
2011-08-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
|
|
AU2004278382B2
(en)
|
2003-09-30 |
2008-09-18 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
WO2005077938A1
(en)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
US7560464B2
(en)
|
2004-04-13 |
2009-07-14 |
Icagen, Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
CA2579143A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
CA2580855A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
BRPI0515482A
(pt)
|
2004-09-20 |
2008-07-22 |
Xenon Pharmaceuticals Inc |
derivados heterocìclicos e seus usos como agentes terapêuticos
|
|
MX2007003327A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
|
|
WO2006034341A2
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
|
US8071603B2
(en)
|
2004-09-20 |
2011-12-06 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
TW200626138A
(en)
|
2004-09-20 |
2006-08-01 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents
|
|
AR051026A1
(es)
|
2004-09-20 |
2006-12-13 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
CA2584167A1
(en)
|
2004-10-22 |
2006-05-04 |
Amgen Inc. |
Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
|
|
WO2006045828A1
(en)
|
2004-10-29 |
2006-05-04 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting bicyclic pyrimidine derivatives
|
|
DE602006014502D1
(de)
*
|
2005-01-14 |
2010-07-08 |
Janssen Pharmaceutica Nv |
Pyrazolopyrimidine als zellzyklus-kinasehemmer
|
|
ES2411975T3
(es)
|
2005-01-14 |
2013-07-09 |
Janssen Pharmaceutica Nv |
Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
|
|
US7301022B2
(en)
|
2005-02-15 |
2007-11-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
US20080096905A1
(en)
*
|
2005-03-25 |
2008-04-24 |
Glaxo Group Limited |
Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
|
|
US20090137550A1
(en)
*
|
2005-03-25 |
2009-05-28 |
Glaxo Group Limited |
Novel Compounds
|
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
|
US8541457B2
(en)
|
2005-06-03 |
2013-09-24 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
|
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
|
HRP20100696T1
(hr)
*
|
2006-03-30 |
2011-01-31 |
Tibotec Pharmaceuticals |
Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini
|
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
AR060635A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
EP2441757A1
(de)
*
|
2006-07-31 |
2012-04-18 |
Praecis Pharmaceuticals Incorporated |
Aurorakinase-Hemmer aus einer codierten Kleinmolekülbibliothek
|
|
WO2008016675A1
(en)
|
2006-08-01 |
2008-02-07 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
|
NZ576278A
(en)
|
2006-10-19 |
2011-12-22 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
|
CA2673965A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Taisho Pharmaceutical Co., Ltd. |
Pyrazolopyrimidine compound
|
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
|
KR20100017441A
(ko)
*
|
2007-04-27 |
2010-02-16 |
아스트라제네카 아베 |
증식성 병태를 치료하기 위한 EphB4 키나제 억제제로서의 N'-(페닐)-N-(모르폴린-4-일-피리딘-2-일)-피리미딘-2,4-디아민 유도체
|
|
AU2008258508A1
(en)
*
|
2007-06-08 |
2008-12-11 |
Bayer Cropscience Ag |
Fungicide heterocyclyl-pyrimidinyl-amino derivatives
|
|
WO2009071535A1
(en)
*
|
2007-12-03 |
2009-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
|
WO2009085185A1
(en)
*
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
|
HUE028347T2
(en)
|
2008-06-10 |
2016-12-28 |
Abbvie Inc |
Tricyclic compounds
|
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
KR101353857B1
(ko)
*
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Cdk 억제제로서 피롤로피리미딘 화합물
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
AU2009320683B2
(en)
*
|
2008-11-28 |
2012-07-19 |
Kowa Company, Ltd. |
Pyridine-3-carboxyamide derivative
|
|
KR20110120878A
(ko)
|
2008-12-29 |
2011-11-04 |
포비어 파마수티칼스 |
치환된 퀴나졸린 화합물
|
|
KR20110116160A
(ko)
|
2009-02-13 |
2011-10-25 |
포비어 파마수티칼스 |
카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-a〕피리딘
|
|
CA2756871A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
US20130023497A1
(en)
*
|
2009-06-08 |
2013-01-24 |
Chunlin Tao |
Triazine Derivatives and their Therapeutical Applications
|
|
EP2440204B1
(de)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nikotinamidverbindungen als kinasemodulatoren
|
|
KR20120091240A
(ko)
|
2009-10-26 |
2012-08-17 |
시그날 파마소티칼 엘엘씨 |
헤테로아릴 화합물의 합성 및 정제 방법
|
|
KR20120102724A
(ko)
|
2009-12-01 |
2012-09-18 |
아보트 러보러터리즈 |
신규한 트리사이클릭 화합물
|
|
ME02800B
(de)
|
2009-12-01 |
2018-01-20 |
Abbvie Inc |
Neue trizyklische verbindungen
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
US8637529B2
(en)
|
2010-06-11 |
2014-01-28 |
AbbYie Inc. |
Pyrazolo[3,4-d]pyrimidine compounds
|
|
AR081960A1
(es)
|
2010-06-22 |
2012-10-31 |
Fovea Pharmaceuticals Sa |
Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
MX379532B
(es)
|
2010-10-25 |
2025-03-10 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
AR084280A1
(es)
|
2010-12-17 |
2013-05-02 |
Hoffmann La Roche |
Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
PT2688887E
(pt)
|
2011-03-23 |
2015-07-06 |
Amgen Inc |
Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
|
|
AU2012245387C1
(en)
|
2011-04-22 |
2016-05-05 |
Signal Pharmaceuticals, Llc |
Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
|
EP3466423B1
(de)
|
2011-10-19 |
2021-07-28 |
Signal Pharmaceuticals, LLC |
Behandlung von krebs mit tor-kinasehemmern
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
BR112014013332B1
(pt)
|
2011-12-02 |
2022-09-06 |
Signal Pharmaceuticals, Llc |
Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
|
|
WO2013106612A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
EP2802577B1
(de)
*
|
2012-01-13 |
2017-03-01 |
Bristol-Myers Squibb Company |
Triazolylsubstituierte pyridylverbindungen als kinaseinhibitoren
|
|
US9242976B2
(en)
|
2012-01-13 |
2016-01-26 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
KR102064626B1
(ko)
|
2012-02-24 |
2020-01-09 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
|
|
WO2013148748A1
(en)
|
2012-03-29 |
2013-10-03 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
CN106008511B
(zh)
*
|
2012-05-14 |
2018-08-14 |
华东理工大学 |
蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
US9611267B2
(en)
|
2012-06-13 |
2017-04-04 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as FGFR inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
CN104812756A
(zh)
*
|
2012-09-26 |
2015-07-29 |
曼凯德公司 |
多激酶通路抑制剂
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
PE20150953A1
(es)
|
2012-11-08 |
2015-06-20 |
Bristol Myers Squibb Co |
Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
|
|
ES2616812T3
(es)
|
2012-11-08 |
2017-06-14 |
Bristol-Myers Squibb Company |
Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
|
|
CN104968664A
(zh)
*
|
2012-12-12 |
2015-10-07 |
山东亨利医药科技有限责任公司 |
作为酪氨酸激酶抑制剂的并环化合物
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9346812B2
(en)
|
2013-01-16 |
2016-05-24 |
Signal Pharmaceuticals, Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
|
US9527857B2
(en)
|
2013-03-15 |
2016-12-27 |
GI Therapeutics, Inc. |
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
WO2014139145A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Hutchison Medipharma Limited |
Novel pyrimidine and pyridine compounds and usage thereof
|
|
US20140271460A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
|
|
EP2986321A1
(de)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Kombinationstherapie mit einem torkinaseinhibitor und einem cytidinanalogon zur behandlung von krebs
|
|
BR112015026257B1
(pt)
|
2013-04-17 |
2022-12-20 |
Signal Pharmaceuticals, Llc |
Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
|
|
MX393164B
(es)
|
2013-04-17 |
2025-03-21 |
Signal Pharm Llc |
Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
|
|
MX368286B
(es)
|
2013-04-17 |
2019-09-27 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
|
|
HK1221150A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪类对癌症的治疗
|
|
CN105339008A
(zh)
|
2013-04-17 |
2016-02-17 |
西格诺药品有限公司 |
用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
|
|
JP6382945B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
|
TWI649318B
(zh)
|
2013-04-19 |
2019-02-01 |
英塞特控股公司 |
作為fgfr抑制劑之雙環雜環
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
NZ629486A
(en)
|
2013-05-29 |
2017-11-24 |
Signal Pharm Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
LT3033086T
(lt)
|
2013-08-14 |
2021-12-27 |
Novartis Ag |
Kombinuota terapija vėžiui gydyti
|
|
RU2016129380A
(ru)
*
|
2013-12-20 |
2018-01-25 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
EP3099672A4
(de)
*
|
2014-01-31 |
2017-09-20 |
ONO Pharmaceutical Co., Ltd. |
Kondensierte imidazolverbindungen
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
HUE053654T2
(hu)
|
2014-03-26 |
2021-07-28 |
Astex Therapeutics Ltd |
FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
KR102479696B1
(ko)
|
2014-03-26 |
2022-12-22 |
아스텍스 테라퓨틱스 리미티드 |
Fgfr 억제제 및 igf1r 억제제의 조합물
|
|
WO2015160868A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
EP3131551A4
(de)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
Feste formen mit 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on und co-former, zusammensetzungen und verfahren zu deren verwendung
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
|
AU2015289929A1
(en)
|
2014-07-14 |
2017-03-02 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
|
WO2016015598A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
AU2016251253B2
(en)
*
|
2015-04-24 |
2020-07-09 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd |
Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
|
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
|
AR105113A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
|
US10618903B2
(en)
|
2015-06-24 |
2020-04-14 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
UY36747A
(es)
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
|
EP3795553B1
(de)
|
2015-07-24 |
2024-05-15 |
Celgene Corporation |
Verfahren zur synthese von (1r,2r,5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin
|
|
EP3353164B1
(de)
|
2015-09-23 |
2021-11-03 |
Janssen Pharmaceutica, N.V. |
Bi-heteroaryl-substituierte 1,4-benzodiazepine und ihre anwendung in der krebsbehandlung
|
|
CA2996857C
(en)
|
2015-09-23 |
2024-05-21 |
Janssen Pharmaceutica Nv |
Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
KR20250010141A
(ko)
|
2015-10-16 |
2025-01-20 |
애브비 인코포레이티드 |
(3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
EA201990187A1
(ru)
*
|
2016-07-01 |
2019-07-31 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
|
CN109789142B
(zh)
*
|
2016-07-01 |
2022-08-23 |
G1治疗公司 |
N-(杂芳基)-吡咯并[3,2-d]嘧啶-2-胺的合成
|
|
MY199852A
(en)
*
|
2016-11-28 |
2023-11-25 |
Teijin Pharma Ltd |
Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
|
|
TWI823845B
(zh)
|
2017-01-06 |
2023-12-01 |
美商G1治療公司 |
用於治療癌症的組合療法
|
|
MY200228A
(en)
|
2017-05-11 |
2023-12-15 |
Bristol Myers Squibb Co |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of carcinoma of the liver characterized by hepatitis b virus infection
|
|
EP4455146A3
(de)
|
2017-06-29 |
2025-01-01 |
G1 Therapeutics, Inc. |
Morphische formen von git38 und verfahren zur herstellung davon
|
|
CN107759596A
(zh)
*
|
2017-12-05 |
2018-03-06 |
安庆奇创药业有限公司 |
一种合成帕博西尼的方法
|
|
CN108299312B
(zh)
*
|
2018-03-29 |
2020-10-30 |
郑州大学第一附属医院 |
一组嘧啶类衍生物及其在制备抗肿瘤药物中的应用
|
|
ES2991427T3
(es)
|
2018-05-04 |
2024-12-03 |
Incyte Corp |
Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
|
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
|
CN120817904A
(zh)
|
2018-08-24 |
2025-10-21 |
法码科思莫斯有限公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021011727A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
|
|
WO2021011724A1
(en)
|
2019-07-18 |
2021-01-21 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
CN114174279B
(zh)
|
2019-08-06 |
2024-07-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂环化合物
|
|
US12570659B2
(en)
|
2019-08-13 |
2026-03-10 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
|
|
WO2021062327A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
|
EP3797776B1
(de)
*
|
2019-09-30 |
2025-07-23 |
Universitätsmedizin Mainz |
Cdk4/6-hemmer zur behandlung von psoriasis
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12391702B2
(en)
|
2020-02-03 |
2025-08-19 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
|
|
CN115335380B
(zh)
|
2020-02-03 |
2024-08-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的三环杂芳基化合物
|
|
US20230135215A1
(en)
*
|
2020-02-28 |
2023-05-04 |
Fochon Biosciences, Ltd. |
Compounds as cdk2/4/6 inhibitors
|
|
AU2021262482A1
(en)
*
|
2020-04-28 |
2023-01-05 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
|
EP4652997A3
(de)
|
2020-05-19 |
2026-03-04 |
Pharmacosmos Holding A/s |
Cyclinabhängige kinasehemmende verbindungen zur behandlung von medizinischen erkrankungen
|
|
CN113801139A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
|
|
CN113801118A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的蝶啶酮衍生物及其应用
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113087708A
(zh)
*
|
2021-04-06 |
2021-07-09 |
南方医科大学 |
一种蝶啶酮类化合物及其应用
|
|
EP4323405A1
(de)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202317106A
(zh)
*
|
2021-08-27 |
2023-05-01 |
南韓商柳韓洋行 |
作為egfr抑制劑之取代胺基吡啶化合物
|
|
TW202328096A
(zh)
|
2021-08-27 |
2023-07-16 |
南韓商柳韓洋行 |
作為egfr抑制劑之含五員雜芳基之胺基吡啶化合物
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
WO2023143135A1
(zh)
*
|
2022-01-28 |
2023-08-03 |
赛诺哈勃药业(成都)有限公司 |
一种喹唑啉衍生物及其用途
|
|
TW202417423A
(zh)
*
|
2022-07-18 |
2024-05-01 |
美商依安彼克醫療有限公司 |
喹唑啉化合物及使用方法
|
|
CN116813621A
(zh)
*
|
2023-06-08 |
2023-09-29 |
江南大学 |
9h嘌呤类化合物及其药物组合物和用途
|
|
WO2025128616A1
(en)
*
|
2023-12-12 |
2025-06-19 |
Genesis Therapeutics, Inc. |
Compounds for treating cancer
|